Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Lung Cancer

Free Subscription 02.12.2019 2 Am J Clin Oncol 2 Ann Thorac Surg 3 Anticancer Res 3 BMC Cancer 1 Br J Cancer 1 Cancer 3 Cancer Chemother Pharmacol 3 Cancer Res 1 Chest 1 Clin Cancer Res 1 Clin Exp Metastasis 3 Clin Lung Cancer 1 Eur J Cardiothorac Surg 4 Hum Pathol 1 J Clin Oncol 1 J Thorac Cardiovasc Surg 4 J Thorac Oncol 4 Lung Cancer 4 Mol Cancer Ther 2 Oncologist 1 PLoS Biol 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Clin Oncol

1. SUKRITHAN V, Barbaro A, Chergui A, Ko B, et al
   Differential Efficacy of Anti-VEGF Antibodies Based on Sex and Race in a Diverse Cohort of Advanced Nonsquamous Non-Small Cell Lung Cancer.
   Am J Clin Oncol. 2019 Nov 18. doi: 10.1097/COC.0000000000000628.
   PubMed     Text format     Abstract available
   
   
2. SHARMA A, Mountjoy LJ, Butterfield RJ, Zhang N, et al
   Expanding the Spectrum of Radiation Necrosis After Stereotactic Radiosurgery (SRS) for Intracranial Metastases From Lung Cancer: A Retrospective Review.
   Am J Clin Oncol. 2019 Nov 18. doi: 10.1097/COC.0000000000000642.
   PubMed     Text format     Abstract available
   
   

   
   Ann Thorac Surg

3. KANG X, Zhang C, Zhou H, Zhang J, et al
   Multiple pulmonary resections for Synchronous and Metachronous Lung Cancer at Two Chinese Centers.
   Ann Thorac Surg. 2019 Nov 22. pii: S0003-4975(19)31724.
   PubMed     Text format     Abstract available
   
   
4. YANG CJ, Brown AB, Deng JZ, Lui NS, et al
   The Oldest Old: A National Analysis of Outcomes for Patients 90 Years or Older With Lung Cancer.
   Ann Thorac Surg. 2019 Nov 12. pii: S0003-4975(19)31582.
   PubMed     Text format     Abstract available
   
   

   
   Anticancer Res

5. CHO E, Than TT, Kim SH, Park ER, et al
   G3BP1 Depletion Increases Radiosensitisation by Inducing Oxidative Stress in Response to DNA Damage.
   Anticancer Res. 2019;39:6087-6095.
   PubMed     Text format     Abstract available
   
   
6. LIU JB, Hu L, Yang Z, Sun YU, et al
   Aurora-A/NF-kB Signaling Is Associated With Radio-resistance in Human Lung Adenocarcinoma.
   Anticancer Res. 2019;39:5991-5998.
   PubMed     Text format     Abstract available
   
   
7. LEHTOMAKI KI, Lahtinen LI, Rintanen N, Kuopio T, et al
   Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case.
   Anticancer Res. 2019;39:5867-5877.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

8. CHEN G, Dong B, Shan G, Zhang X, et al
   Choice of immobilization of stereotactic body radiotherapy in lung tumor patient by BMI.
   BMC Cancer. 2019;19:583.
   PubMed     Text format     Abstract available
   
   
9. KATSUI K, Ogata T, Watanabe K, Katayama N, et al
   Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis.
   BMC Cancer. 2019;19:1144.
   PubMed     Text format     Abstract available
   
   
10. KETTUNEN E, Savukoski S, Salmenkivi K, Bohling T, et al
    CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
    BMC Cancer. 2019;19:507.
    PubMed     Text format     Abstract available
    
    

    
    Br J Cancer

11. PARK W, Mezquita L, Okabe N, Chae YK, et al
    Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.
    Br J Cancer. 2019 Nov 25. pii: 10.1038/s41416-019-0643.
    PubMed     Text format     Abstract available
    
    

    
    Cancer

12. PAPADIMITRAKOPOULOU VA, Han JY, Ahn MJ, Ramalingam SS, et al
    Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
    Cancer. 2019 Nov 26. doi: 10.1002/cncr.32503.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Chemother Pharmacol

13. LI CSW, Sweeney K, Cronenberger C
    Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin((R))) in patients with advanced non-squamous non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2019 Nov 26. pii: 10.1007/s00280-019-03946.
    PubMed     Text format     Abstract available
    
    
14. ALHARBI AF, Kratzke RA, D'Cunha J, Maddaus MA, et al
    Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.
    Cancer Chemother Pharmacol. 2019;83:387-391.
    PubMed     Text format     Abstract available
    
    
15. KOSTEK O, Hacioglu MB, Sakin A, Demir T, et al
    Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
    Cancer Chemother Pharmacol. 2019;83:115-122.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

16. HAVEL JJ
    MEK Inhibitors in Lung Cancer-You Can Teach an Old Drug New Tricks.
    Cancer Res. 2019;79:5699-5701.
    PubMed     Text format     Abstract available
    
    
17. ROMAN M, Lopez I, Guruceaga E, Baraibar I, et al
    Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.
    Cancer Res. 2019;79:625-638.
    PubMed     Text format     Abstract available
    
    
18. NEEL DS, Allegakoen DV, Olivas V, Mayekar MK, et al
    Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
    Cancer Res. 2019;79:546-556.
    PubMed     Text format     Abstract available
    
    

    
    Chest

19. LIU B, Dharmarajan K, Henschke CI, Taioli E, et al
    State-level variations in the utilization of lung cancer screening among fee-for-service Medicare beneficiaries: an analysis of the 2015-2017 Physician and Other Supplier data.
    Chest. 2019 Nov 21. pii: S0012-3692(19)34223-0. doi: 10.1016/j.chest.2019.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

20. TAMMINGA M, de Wit S, Van De Wauwer C, van den Bos H, et al
    Release of circulating tumor cells during surgery for non-small cell lung cancer: are they what they appear to be?
    Clin Cancer Res. 2019 Nov 26. pii: 1078-0432.CCR-19-2541.
    PubMed     Text format     Abstract available
    
    

    
    Clin Exp Metastasis

21. MASUDA C, Sugimoto M, Wakita D, Monnai M, et al
    Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model.
    Clin Exp Metastasis. 2019 Nov 25. pii: 10.1007/s10585-019-10008.
    PubMed     Text format     Abstract available
    
    

    
    Clin Lung Cancer

22. JACOBS CD, Gao J, Wang X, Clarke JM, et al
    Definitive Radiotherapy for Inoperable Stage IIB Non-small-cell Lung Cancer: Patterns of Care and Comparative Effectiveness.
    Clin Lung Cancer. 2019 Oct 19. pii: S1525-7304(19)30270.
    PubMed     Text format     Abstract available
    
    
23. XIA H, Xue X, Ding H, Ou Q, et al
    Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.
    Clin Lung Cancer. 2019 Sep 26. pii: S1525-7304(19)30262.
    PubMed     Text format     Abstract available
    
    
24. BEGNAUD A, Yang P, Robichaux C, Rubin N, et al
    Evidence That Established Lung Cancer Mortality Disparities in American Indians Are Not Due to Lung Cancer Genetic Testing and Targeted Therapy Disparities.
    Clin Lung Cancer. 2019 Oct 30. pii: S1525-7304(19)30286.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cardiothorac Surg

25. HENNON MW, DeGraaff LH, Groman A, Demmy TL, et al
    The association of nodal upstaging with surgical approach and its impact on long-term survival after resection of non-small-cell lung cancer.
    Eur J Cardiothorac Surg. 2019 Nov 25. pii: 5640487. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Hum Pathol

26. LINDHOLM KE, Kalhor N, Moran CA
    Osteoclast-like giant cell-rich carcinomas of the lung: a clinicopathological, immunohistochemical, and molecular study of 3 cases.
    Hum Pathol. 2019;85:168-173.
    PubMed     Text format     Abstract available
    
    
27. SVAJDLER M, Mezencev R, Saskova B, Ondic O, et al
    Triple marker composed of p16, CD56, and TTF1 shows higher sensitivity than INSM1 for diagnosis of pulmonary small cell carcinoma: proposal for a rational immunohistochemical algorithm for diagnosis of small cell carcinoma in small biopsy and cytology
    Hum Pathol. 2019;85:58-64.
    PubMed     Text format     Abstract available
    
    
28. ZHANG J, Sun J, Zhang Z, Wang A, et al
    Driver mutation profiles and clinicopathological correlation in pulmonary adenocarcinoma with a micropapillary component.
    Hum Pathol. 2019;85:242-250.
    PubMed     Text format     Abstract available
    
    
29. WANG Y, Piao J, Wang Q, Cui X, et al
    Paip1 predicts poor prognosis and promotes tumor progression through AKT/GSK-3beta pathway in lung adenocarcinoma.
    Hum Pathol. 2019;86:233-242.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

30. ROTOW JK, Janne PA
    What's Old Is New Again: Revisiting Up-Front Chemotherapy in EGFR-Mutated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Nov 27:JCO1902724. doi: 10.1200/JCO.19.02724.
    PubMed     Text format    
    
    

    
    J Thorac Cardiovasc Surg

31. ABBAS AE
    Commentary: Robotic anatomic lung resection: Raising the bar of our expectations in treating lung cancer.
    J Thorac Cardiovasc Surg. 2019 Sep 24. pii: S0022-5223(19)32045.
    PubMed     Text format    
    
    

    
    J Thorac Oncol

32. PARK S, Lee SH, Park K
    In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing.
    J Thorac Oncol. 2019;14:e279-e280.
    PubMed     Text format    
    
    
33. LUO P, Lin A, Li K, Wei T, et al
    DDR Pathway Alteration, Tumor Mutation Burden, and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole Exome and Targeted Gene Sequencing.
    J Thorac Oncol. 2019;14:e276-e279.
    PubMed     Text format    
    
    
34. PASSIGLIA F, Calandri M, Guerrera F, Malapelle U, et al
    Lung Cancer in Italy.
    J Thorac Oncol. 2019;14:2046-2052.
    PubMed     Text format    
    
    
35. PASTORINO U, Tagliabue E
    Non-Human Determinants of Lung Cancer Outcome: A Target for Inhibition of Pro-Metastatic Effect of Surgery, Triggered by Postoperative Bacterial Pneumonia.
    J Thorac Oncol. 2019;14:2039-2041.
    PubMed     Text format    
    
    

    
    Lung Cancer

36. SONG T, Jiang L, Lin Y
    Comment on: 'Correlation of Tumor Spread through Air Spaces and Clinicopathological Characteristics in Surgically Resected Lung Adenocarcinomas'.
    Lung Cancer. 2019;132:150.
    PubMed     Text format    
    
    
37. TENDLER S, Holmqvist M, Wagenius G, Lewensohn R, et al
    Educational level, management and outcomes in small-cell lung cancer (SCLC): A population-based cohort study.
    Lung Cancer. 2019;139:111-117.
    PubMed     Text format     Abstract available
    
    
38. GIAJ-LEVRA N, Giaj Levra M, Berghmans T, Novello S, et al
    Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter?
    Lung Cancer. 2019 Nov 13. pii: S0169-5002(19)30719.
    PubMed     Text format    
    
    
39. HSIEH MS, Lin MW
    Response to comment on: "Correlation of Tumor Spread through Air Spaces and Clinicopathological Characteristics in Surgically Resected Lung Adenocarcinomas."
    Lung Cancer. 2019;132:151.
    PubMed     Text format    
    
    

    
    Mol Cancer Ther

40. CHAN SH, Tsai KW, Chiu SY, Kuo WH, et al
    Identification of the Novel Role of CD24 as an Oncogenesis Regulator and Therapeutic Target for Triple-Negative Breast Cancer.
    Mol Cancer Ther. 2019;18:147-161.
    PubMed     Text format     Abstract available
    
    
41. CHAI D, Shan H, Wang G, Zhang Q, et al
    Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8(+) T-cell Responses.
    Mol Cancer Ther. 2019;18:323-334.
    PubMed     Text format     Abstract available
    
    
42. PAPADAKI MA, Stoupis G, Theodoropoulos PA, Mavroudis D, et al
    Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.
    Mol Cancer Ther. 2019;18:437-447.
    PubMed     Text format     Abstract available
    
    
43. STAUDACHER AH, Li Y, Liapis V, Hou JJC, et al
    APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo.
    Mol Cancer Ther. 2019;18:335-345.
    PubMed     Text format     Abstract available
    
    

    
    Oncologist

44. RAGHAVAN D, Wheeler M, Doege D, Doty JD 2nd, et al
    Initial Results from Mobile Low-Dose Computerized Tomographic Lung Cancer Screening Unit: Improved Outcomes for Underserved Populations.
    Oncologist. 2019 Nov 26. pii: theoncologist.2019-0802.
    PubMed     Text format     Abstract available
    
    
45. AVANCINI A, Sartori G, Gkountakos A, Casali M, et al
    Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?
    Oncologist. 2019 Nov 26. pii: theoncologist.2019-0463.
    PubMed     Text format     Abstract available
    
    

    
    PLoS Biol

46. BENBENISHTY A, Gadrich M, Cottarelli A, Lubart A, et al
    Prophylactic TLR9 stimulation reduces brain metastasis through microglia activation.
    PLoS Biol. 2019;17:e2006859.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

47. MINCHOM A, Mak D, Gunapala R, Walder D, et al
    A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma.
    PLoS One. 2019;14:e0225509.
    PubMed     Text format     Abstract available
    
    
48. ZHAO JG, Wang JF, Feng JF, Jin XY, et al
    HHIP overexpression inhibits the proliferation, migration and invasion of non-small cell lung cancer.
    PLoS One. 2019;14:e0225755.
    PubMed     Text format     Abstract available
    
    
49. PO JW, Ma Y, Balakrishna B, Brungs D, et al
    Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status.
    PLoS One. 2019;14:e0211866.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: